Pfizer isn’t alone in facing disappointing Covid-19 sales. Last year, the shot, as well as the Covid-19 drug Paxlovid, powered Pfizer past $100 billion in sales. The company is now estimating $12.5 billion in Covid-19 vaccine and drug sales in 2023, and $8 billion in Covid-19 vaccine and drug sales in 2024. Investors especially punished the company when, in October, it lowered its 2023 sales forecasts for the vaccine, drug and the company overall. Elsewhere around Pfizer, workers worry they will be next.

Source: Wall Street Journal December 15, 2023 10:20 UTC